Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Breast Cancer Res Treat. 2018 Mar 9;170(2):293–302. doi: 10.1007/s10549-018-4745-7

Table 2.

Recurrence free survival and overall survival correlation with PD-L1 and stromal tumor infiltrating lymphocytes

Recurrence Free Survival
Overall Survival
Overall Recurrence No recurrence p-value Overall Death No death p-value
(n=182) (n=30) (n=152) (n=191) (n=20) (n=171)
TIL-Str 25 (0-85) 16 (0-50) 25 (0-85) 0.101 24 (0-85) 6 (3-85) 25 (0-80) 0.005
28-8 in tumor 1.2 (0-85) 0 (0-11.7) 1.7 (0-85) 0.055 1.2 (0-85) 2.3 (0-66.7) 0.8 (0-85) 0.618
28-8 in TILs 4.2 (0-91.7) 0 (0-26.7) 5 (0-91.7) 0.011 4 (0-91.7) 1 (0-60) 5 (0-91.7) 0.300
22C3 in tumor 0 (0-73.3) 0 (0-0.8) 0 (0-73.3) 0.149 0 (0-73.3) 0 (0-51.7) 0 (0-73.3) 0.388
22C3 in TILs 0.8 (0-66.7) 0 (0-27) 0.8 (0-66.7) 0.566 0.8 (0-66.7) 0 (0-61.7) 0.8 (0-66.7) 0.140